Q3 miss, underlying in line

CoinShares Announces Q3 2024 Results

CoinShares Announces Q3 2024 Results 5th November 2024 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European investment company specialising in digital assets, has today published its  for the quarter ending 30th September 2024. Jean-Marie Mognetti, Chief Executive Officer of CoinShares said: “In Q3 2024, we concentrated on executing our strategy and preparing for a promising Q4 and the upcoming year. A key achievement was the change in our accounting policy for ...

CoinShares tillkännager resultaten för tredje kvartalet 2024

CoinShares tillkännager resultaten för tredje kvartalet 2024 5 november 2024 | SAINT HELIER, Jersey | CoinShares International Limited ("CoinShares" eller "koncernen") (Nasdaq Stockholm: CS; US OTCQX: CNSRF), det ledande europeiska investeringsföretaget specialiserat på digitala tillgångar, har idag publicerat sitt  för det tredje kvartalet som slutade den 30 september 2024. Jean-Marie Mognetti, Verkställande direktör för CoinShares sa: “I Q3 2024 fokuserade vi på att genomföra vår strategi och på att förbereda oss för ett lovande fjärde kvartal och det kom...

Electro Optic Systems - Growth from defence

Electro Optic Systems (EOS) is an optic technology company specialising in defence applications, primarily remote weapons systems (RWS) and maritime communications. The company is benefiting from increased defence spending, is well-positioned in the new frontier of drone warfare and brings optionality in future battlefield arenas of high-energy laser weapons (HELWs) and space. Improved H1 results, a strong balance sheet and an extensive pipeline position EOS to benefit from such dynamics.

Smiths News - FY24 trading good, special dividend proposed

Smiths News’ FY24 trading was robust and results came in ahead of consensus. This, along with the debt refinancing announced in May, has resulted in lower average debt, which in turn has allowed the company to implement its revised capital allocation policy (communicated in May) and its diversification ambitions. Furthermore, it has lifted its total ordinary dividend from 4.15p to 5.15p/share and announced a ‘special’ dividend of a further 2.0p/share.

IRLAB Therapeutics - Progress across the pipeline in Q324

IRLAB’s Q324 results highlighted progress across its clinical pipeline. Pirepemat cleared its final safety review and completed patient enrolment in the Phase IIb trial, making way for top-line readouts in Q125. IRL757 also made headway, reporting positive interim data from the first Phase I study and the initiation of a second study in older adults, triggering a US$2.5m (SEK26.6m) milestone payment from MSRD. Mesdopetam reported support from regulators in Germany and Portugal for the planned Phase III design, bolstering upcoming discussions with the EMA. This comes amid efforts by IRLAB towar...